Posts

Showing posts with the label Spinal Muscular Atrophy (SMA) Emerging Therapy

Spinal Muscular Atrophy (SMA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Spinal Muscular Atrophy (SMA) Emerging Therapy and TPP Insights Thelansis’s “Spinal Muscular Atrophy (SMA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product...

Spinal Muscular Atrophy (SMA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034

Spinal Muscular Atrophy (SMA) Emerging Therapy Thelansis’s “Spinal Muscular Atrophy (SMA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder primarily characterized by the progressive, irreversible loss and degeneration of alpha motor neurons in the anterior horn of the spinal cord and brain stem, leading to profound, typically symmetric, muscle weakness and atrophy, most severely affecting the proximal muscles and eventually causing paralysis in severe cases. This condition is overwhelmingly caused by mutations or deletions in the Survival Motor Neuron 1 ( SMN1 ) gene, which results in a deficiency of the cr...